Biomarin Pharmaceutical Inc BMRN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BMRN is a good fit for your portfolio.
News
-
Texas Pacific Land, Altair Engineering Hit 52-Week Highs on S&P MidCap 400 Inclusion
-
CrowdStrike, KKR and GoDaddy to join S&P 500
-
BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme — Update
-
BioMarin Pharmaceutical Gets DOJ Subpoena for Documents Related to Vimizim, Naglazyme
-
BioMarin Pharmaceutical's Achondroplasia Treatment Gets FDA Approval for All Pediatric Patients
-
FDA approves BioMarin's gene therapy drug for hemophilia
Trading Information
- Previous Close Price
- €78.08
- Day Range
- €78.42–78.68
- 52-Week Range
- €68.18–90.16
- Bid/Ask
- €78.20 / €78.70
- Market Cap
- €14.89 Bil
- Volume/Avg
- 0 / 15
Key Statistics
- Price/Earnings (Normalized)
- 100.84
- Price/Sales
- 6.64
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 3,401
- Website
- https://www.biomarin.com
Competitors
Valuation
|
Metric
|
BMRN
|
SNY
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | 100.84 | 10.15 | 19.21 |
Price/Book Value | 3.16 | 1.52 | 1.69 |
Price/Sales | 6.64 | 2.29 | 2.82 |
Price/Cash Flow | 32.47 | 11.31 | 18.12 |
Price/Earnings
BMRN
SNY
PFE
Financial Strength
|
Metric
|
BMRN
|
SNY
|
PFE
|
|---|---|---|---|
Quick Ratio | 1.55 | 0.83 | 0.67 |
Current Ratio | 2.74 | 1.27 | 1.05 |
Interest Coverage | 11.35 | 8.40 | −0.26 |
Quick Ratio
BMRN
SNY
PFE
Profitability
|
Metric
|
BMRN
|
SNY
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | 5.82% | — | 3.77% |
Return on Equity (Normalized) | 7.98% | — | 8.51% |
Return on Invested Capital (Normalized) | 5.81% | — | 5.75% |
Return on Assets
BMRN
SNY
PFE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Dltssbjgs | Hwgjsh | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dsgsvjb | Wbzppk | $114.2 Bil | |||
| Moderna Inc
MRNA
| Gzbdjpdml | Fqjyn | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Ctwpbwz | Rlr | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Gqlxrbyp | Gqgby | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kgqygvxj | Lvfmrf | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Fszxsvkvb | Cqxpfh | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Vxlswwzbs | Ntzrl | $12.8 Bil | |||
| Incyte Corp
INCY
| Hvckrlwzx | Wpgcwr | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Tsmtvrhnrz | Mhqrn | $12.2 Bil |